Japan Again Postpones Approval Of Shionogi COVID Antiviral
Decision To Await Phase III Data
Executive Summary
Xocova’s emergency approval stymied by uncertainties over efficacy and other characteristics that could effectively limit its use, prompting decision to await Phase III data later this year.
You may also be interested in...
Third Time Lucky As Japan Finally Approves Shionogi’s Oral COVID Antiviral
Shionogi’s once-daily oral COVID-19 antiviral finally gets Japan approval after being considered for the third time by an expert panel, paving the way for public availability of the country’s first such home-grown option in early December.
Shionogi Reveals Strategy For COVID-19 Drug Xocova
Shionogi is hoping to demonstrate the efficacy of its oral COVID-19 candidate Xocova through an appropriate primary endpoint in its Phase III trial, while the Japanese firm is also eyeing global expansion for the drug should a world-first domestic approval be granted.
New COVID Therapeutic Development Hitting Regulatory Wall At US FDA
FDA trial design criteria pose challenges for new COVID therapeutic development, frustrating companies and NIH and prompting a tense meeting earlier this summer, according to audio obtained by the Pink Sheet.